Pages

August 22, 2014

SENS Rejuvenation Biotechnology Conference-Cancer Session

For the afternoon sessions at the SENS conference, attendees had the option of learning about advances in Cancer, Parkinsons, or the Risk-Benefit Analysis in Therapies for Disease and Disabilities of Aging. Deciding to venture away from the investment track and into a more clinical focus, I selected the Cancer track, kicked off by by Judith Campisi from Buck Institute for Research on Aging. 
Judith Campisi

SENS Rejuvenation Biotechnology Conference-Keynote: Jim O'Neill

This morning at the SENS conference, Edward James Olmos kicks off the day with some opening remarks before Jim O'Neill delivers his keynote.



Mithril, the two year old investment firm which Jim serves as COO, specializes in emerging technology start-ups.  For example, they recently invested in Magforce, a nanotechnology-based cancer treatment company, and  Helion Energy, another impressive start up which focuses on fusion energy. Thiel investment firm Breakout Labs has invested in a company called Immusoft, whose mission is to develop a completely new platform for delivering medicines, by programming a patient’s own cells to become miniature drug factories (how freaking awesome is that?!) 

Update from Rejuvenation Biotech - The Tricorder is coming!

Daniel Kraft spoke about Scanadu, a company competing for the Tricorder X-Prize. Scanadu is to begin FDA trials of their device this fall!

Star Trek Feature Quality Film Funded by Kickstarter

Axanar is the independent Star Trek film which proves that a feature-quality Star Trek film can be made on a small budget.

Their 20-minute short film, Prelude to Axanar, premiered Saturday, July 26th, 2014, at San Diego Comic Con and features Richard Hatch, Tony Todd, Kate Vernon, JG Hertzler and Gary Graham, who reprises his role of Soval from "Enterprise". The makeup was done by Academy Award winner Kevin Haney and Star Trek veteran Brad Look and Make Up Effects Lab. Top that off with the amazing visual effects of Tobias Richter and The Light Works, and sound by Academy Award winner Frank Serafine, and the result is Prelude to Axanar: something unlike anything you have ever seen before.

Donate to the kickstarter for the Axanar movie

This Kickstarter is for the full-length feature Axanar. Unlike the short film, which we shot in two days and cost $75,000, the 90-minute Axanar feature will take about 20 days and cost about $650,000.

$35 get an Axanar fleet patch
$75 get the Blueray with extra plus lower level awards
$250 appear as a hero casualty in the movie


The Star Trek Axanar website is here



August 21, 2014

SENS Rejuvenation Biotechnology- Economic Impact of an Aging Population on the Healthcare System

The second to last panel discussion features David Brindley as Moderator, Catalina Hoffman and Peter Nakada. 

I find it interesting, how the early years and the last years of life mimic each other. For many of the aging population, it is difficult to care for themselves to the degree they were able to in the past. Embarrassment and isolation can lead to depression, yet some companies aim to enhance the lives of these individuals, spurring development of new solutions, services and products that transform the quality of life of seniors. 


Introducing Hoffmann Elderly, Vitalia and The Hoffmann Method, which is a new system of personal care that takes into account the physical, psychological, cognitive and social needs of its clients, with the objective of improving the quality of life for seniors and their families. This method improves quality of life for this population. If this helps people live longer, albeit not necessarily without disease, what are the economic effects we can expect to see?

Update from Rejuvenation Biotech - 3D Printed Food

Gabor Forgacs, CEO of Organovo, says by 2015 there will be 9 billion hungry people on this Earth, and raising cattle for meat is to resource intensive. What if you could 3D print burgers to feed the world's growing population? Would you eat a burger grown in a lab?

SENS Rejuvenation Biotechnology Conference-Toward a New Investment Paradigm

L-R: David Brindley, Jim O'Neill, Michael West, Neil Littman, Bernard Siegel
So, I opted for the investment panel, instead of the clinical tracks of Alzheimers and Cardiovascular Disease. Moderated by David Brindley, panelists take turns presenting their perspective, and we start off with Neil Littman from CIRM (California Institute of Regenerative Medicine).